{"AlternateComparison":false,"RelatedProducts":false,"Specification":true,"FeatureBenefit":false}
BD Onclarity™ BD Onclarity™ HPV Assay

BD Viper™ Neutralization Pouch

Icon to close the modal
Support
Becton, Dickinson and Company
Phone Icon
0124-4124300
bd_india@bd.com
Modal Close Icon
Contact Us

 

 

Icon to close thank you modal
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Address
Location Icon
6th Floor Signature Tower - B, South City I, NH 8 Gurgaon, 122001, Haryana
Overview

The BD Onclarity™ HPV Assay is FDA-approved for extended genotyping, offering the flexibility you need to adapt to changing screening guidelines and evolving patient management guidance.

FDA approved for all three screening paradigms:

In the post-vaccination era the prevalence of high-risk genotypes may change making it crucial to identify high-risk genotypes individually.

  • Extended genotyping supports risk stratification and persistence monitoring to guide patient management1-5
  • Genotypes 16 and 18 account for 70% of invasive cancer worldwide, but their prevalence is declining as vaccination rates increase.6-9
  • Genotypes 31,33,58 have a CIN3+ risk similar to genotype 18, but 51,35,39,68,56,59,66 have a much lower risk.10-11
true
Features and Benefits
Promotional Story
false
References
false
Specification

GTIN - each

00382904413545

1

GTIN - Shelfpack

30382904413546

12


Quantity - Shelfpack

12


Shelf Life (Days)

0

GTIN

GTIN - each 00382904413545 1
GTIN - Shelfpack 30382904413546 12

Packaging

Quantity - Shelfpack 12

Storage and Handling

Shelf Life (Days) 0
References
false
Resources
References
false
Related Products
RELATED PRODUCTS NOT AVAILABLE
References
false